» Articles » PMID: 26097457

Computational Identification of Potential Multi-drug Combinations for Reduction of Microglial Inflammation in Alzheimer Disease

Overview
Journal Front Pharmacol
Date 2015 Jun 23
PMID 26097457
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Like other neurodegenerative diseases, Alzheimer Disease (AD) has a prominent inflammatory component mediated by brain microglia. Reducing microglial inflammation could potentially halt or at least slow the neurodegenerative process. A major challenge in the development of treatments targeting brain inflammation is the sheer complexity of the molecular mechanisms that determine whether microglia become inflammatory or take on a more neuroprotective phenotype. The process is highly multifactorial, raising the possibility that a multi-target/multi-drug strategy could be more effective than conventional monotherapy. This study takes a computational approach in finding combinations of approved drugs that are potentially more effective than single drugs in reducing microglial inflammation in AD. This novel approach exploits the distinct advantages of two different computer programming languages, one imperative and the other declarative. Existing programs written in both languages implement the same model of microglial behavior, and the input/output relationships of both programs agree with each other and with data on microglia over an extensive test battery. Here the imperative program is used efficiently to screen the model for the most efficacious combinations of 10 drugs, while the declarative program is used to analyze in detail the mechanisms of action of the most efficacious combinations. Of the 1024 possible drug combinations, the simulated screen identifies only 7 that are able to move simulated microglia at least 50% of the way from a neurotoxic to a neuroprotective phenotype. Subsequent analysis shows that of the 7 most efficacious combinations, 2 stand out as superior both in strength and reliability. The model offers many experimentally testable and therapeutically relevant predictions concerning effective drug combinations and their mechanisms of action.

Citing Articles

Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals.

Joshi A, Todd S, Finn D, McClean P, Wong-Lin K BMC Med Inform Decis Mak. 2022; 22(1):262.

PMID: 36207697 PMC: 9547465. DOI: 10.1186/s12911-022-01892-9.


Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease.

Joshi A, Wang D, Watterson S, McClean P, Behera C, Sharp T Neuropharmacology. 2020; 174:108118.

PMID: 32380022 PMC: 7322519. DOI: 10.1016/j.neuropharm.2020.108118.


Dreaming of a New World Where Alzheimer's Is a Treatable Disorder.

Catania M, Giaccone G, Salmona M, Tagliavini F, Di Fede G Front Aging Neurosci. 2019; 11:317.

PMID: 31803047 PMC: 6873113. DOI: 10.3389/fnagi.2019.00317.


Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.

Geerts H, Wikswo J, van der Graaf P, Bai J, Gaiteri C, Bennett D CPT Pharmacometrics Syst Pharmacol. 2019; 9(1):5-20.

PMID: 31674729 PMC: 6966183. DOI: 10.1002/psp4.12478.


Network pharmacology study on the active components of and the mechanism of their effect against cerebral ischemia.

Niu B, Zhang H, Li C, Yan F, Song Y, Hai G Drug Des Devel Ther. 2019; 13:3009-3019.

PMID: 31564827 PMC: 6733351. DOI: 10.2147/DDDT.S207955.


References
1.
Lim G, Yang F, Chu T, Chen P, BEECH W, Teter B . Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000; 20(15):5709-14. PMC: 6772529. View

2.
Kettenmann H, Hanisch U, Noda M, Verkhratsky A . Physiology of microglia. Physiol Rev. 2011; 91(2):461-553. DOI: 10.1152/physrev.00011.2010. View

3.
Wong W . Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation. Front Cell Neurosci. 2013; 7:22. PMC: 3595516. DOI: 10.3389/fncel.2013.00022. View

4.
Wang L, Xu Y, Zhang X . Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials. Leuk Lymphoma. 2013; 55(7):1479-88. DOI: 10.3109/10428194.2013.838232. View

5.
Miklossy J . Chronic inflammation and amyloidogenesis in Alzheimer's disease -- role of Spirochetes. J Alzheimers Dis. 2008; 13(4):381-91. DOI: 10.3233/jad-2008-13404. View